Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults
Scilex Holding Company (NASDAQ: SCLX) has amended its license agreement with Romeg Therapeutics for Gloperba®, expanding from US-only to worldwide commercialization rights. Gloperba® is the first and only liquid oral colchicine formulation FDA-approved for preventing painful gout flares in adults.
The medication offers unique advantages through its liquid format, enabling precision dosing particularly beneficial for the over 70% of gout patients with comorbid conditions requiring dose adjustments. The 0.6mg per 5ml dosage provides flexibility for patients who have difficulty swallowing pills and allows for dose reduction in patients with severe renal impairment (0.3 mg/day).
The global gout patient population has significantly increased from 22 million to 53 million over the past 30 years, with a worldwide incidence rate of 0.1-0.3% of the population.
Scilex Holding Company (NASDAQ: SCLX) ha modificato il suo contratto di licenza con Romeg Therapeutics per Gloperba®, estendendo i diritti di commercializzazione da solo negli Stati Uniti a livello mondiale. Gloperba® è la prima e unica formulazione orale liquida di colchicina approvata dalla FDA per prevenire attacchi dolorosi di gotta negli adulti.
Il farmaco offre vantaggi unici grazie al suo formato liquido, che consente una dosaggio preciso particolarmente utile per oltre il 70% dei pazienti con gotta affetti da condizioni comorbide che richiedono aggiustamenti della dose. Il dosaggio di 0,6 mg per 5 ml offre flessibilità ai pazienti che hanno difficoltà a deglutire le pillole e consente una riduzione della dose nei pazienti con grave insufficienza renale (0,3 mg/giorno).
La popolazione globale di pazienti con gotta è aumentata significativamente da 22 milioni a 53 milioni negli ultimi 30 anni, con un tasso di incidenza mondiale dello 0,1-0,3% della popolazione.
Scilex Holding Company (NASDAQ: SCLX) ha modificado su acuerdo de licencia con Romeg Therapeutics para Gloperba®, ampliando los derechos de comercialización de solo EE. UU. a nivel mundial. Gloperba® es la primera y única formulación líquida oral de colchicina aprobada por la FDA para prevenir crisis dolorosas de gota en adultos.
El medicamento ofrece ventajas únicas gracias a su formato líquido, lo que permite un dosificación precisa, especialmente beneficiosa para más del 70% de los pacientes con gota que tienen comorbilidades que requieren ajustes de dosis. La dosis de 0,6 mg por 5 ml brinda flexibilidad para los pacientes que tienen dificultad para tragar píldoras y permite la reducción de dosis en pacientes con insuficiencia renal severa (0,3 mg/día).
La población global de pacientes con gota ha aumentado significativamente de 22 millones a 53 millones en los últimos 30 años, con una tasa de incidencia mundial del 0,1-0,3% de la población.
Scilex Holding Company (NASDAQ: SCLX)는 Romeg Therapeutics와의 라이센스 계약을 수정하여 Gloperba®의 미국을 넘어 전 세계 상용화 권리를 확장했습니다. Gloperba®는 성인의 고통스러운 통풍 발작을 예방하기 위해 FDA의 승인을 받은 최초이자 유일한 경구 액상 콜히친 제형입니다.
이 약물은 액상 제형으로 인해 독특한 이점을 제공하며, 이는 70% 이상의 통풍 환자가 복용량 조정이 필요한 동반 질환을 갖고 있을 때 특히 유용합니다. 5ml당 0.6mg의 용량은 알약을 삼키기 어려운 환자에게 유연성을 제공하며, 심각한 신장 기능 저하 환자에게는 복용량을 줄일 수 있게 해줍니다 (0.3 mg/일).
전 세계 통풍 환자 수는 지난 30년 동안 2200만 명에서 5300만 명으로 크게 증가했으며, 인구의 0.1-0.3%의 전 세계 발병률을 보이고 있습니다.
Scilex Holding Company (NASDAQ: SCLX) a modifié son contrat de licence avec Romeg Therapeutics pour Gloperba®, étendant les droits de commercialisation des États-Unis à un droit mondial. Gloperba® est la première et unique formulation orale liquide de colchicine approuvée par la FDA pour prévenir les crises douloureuses de goutte chez les adultes.
Ce médicament offre des avantages uniques grâce à son format liquide, permettant un dosage précis, particulièrement bénéfique pour plus de 70 % des patients atteints de goutte ayant des comorbidités nécessitant des ajustements de dose. La posologie de 0,6 mg par 5 ml offre de la flexibilité pour les patients ayant des difficultés à avaler des comprimés et permet une réduction de la dose chez les patients présentant une insuffisance rénale sévère (0,3 mg/jour).
La population mondiale de patients souffrant de goutte a considérablement augmenté, passant de 22 millions à 53 millions au cours des 30 dernières années, avec un taux d'incidence mondial de 0,1 à 0,3 % de la population.
Scilex Holding Company (NASDAQ: SCLX) hat seine Lizenzvereinbarung mit Romeg Therapeutics für Gloperba® geändert, indem die Vermarktungsrechte von nur den USA auf weltweit ausgeweitet wurden. Gloperba® ist die erste und einzige flüssige orale Colchicin-Formulierung, die von der FDA zur Prävention schmerzhafter Gichtanfälle bei Erwachsenen zugelassen ist.
Das Medikament bietet durch sein flüssiges Format einzigartige Vorteile, die eine präzise Dosierung ermöglichen, was besonders vorteilhaft für über 70% der Gichtpatienten ist, die an Begleiterkrankungen leiden, die Anpassungen der Dosis erfordern. Die Dosierung von 0,6 mg pro 5 ml bietet Flexibilität für Patienten, die Schwierigkeiten beim Schlucken von Tabletten haben, und ermöglicht eine Dosisreduzierung bei Patienten mit schwerer Niereninsuffizienz (0,3 mg/Tag).
Die globale Patientenzahl mit Gicht hat sich in den letzten 30 Jahren von 22 Millionen auf 53 Millionen erheblich erhöht, mit einer weltweiten Inzidenzrate von 0,1-0,3% der Bevölkerung.
- Expansion from US-only to worldwide commercialization rights for Gloperba®
- First and only FDA-approved liquid colchicine formulation for gout flare prevention
- Large target market with over 70% of gout patients potentially benefiting from flexible dosing
- Growing market opportunity with global gout population increasing from 22M to 53M patients
- 17% of gout patients on colchicine experience severe gastrointestinal side effects
- Less than 50% of gout patients receive definitive urate-lowering therapy
- High non-persistence rates in gout treatment adherence
Insights
The amendment to expand Gloperba's commercialization rights from US-only to worldwide represents a significant market opportunity. With the global gout patient population having grown from 22 million to 53 million over the past 30 years, this liquid formulation addresses critical market gaps. The unique selling proposition lies in its flexible dosing capability, particularly valuable for the 70% of gout patients with comorbidities requiring dose adjustments.
Think of Gloperba as a "smart" version of traditional colchicine - instead of a one-size-fits-all pill, it's like having a adjustable thermostat for medication dosing. This precision dosing feature could drive market penetration, especially in populations with renal impairment or difficulty swallowing pills. With gout prevalence increasing globally due to rising obesity rates and aging populations, the timing of this worldwide rights acquisition aligns well with market trends.
The amendment strategically positions Scilex to capture value in both established and emerging markets. The financial implications extend beyond direct sales potential - the liquid formulation could reduce healthcare costs associated with complications from improper dosing and improve patient compliance, particularly important given that 17% of colchicine users experience severe gastrointestinal side effects.
For investors, this represents a potential revenue diversification play. Breaking it down simply: Scilex now has global rights to a differentiated product in a growing market with clear unmet needs. The ability to adjust doses precisely could lead to better insurance coverage and reimbursement rates compared to standard colchicine formulations, potentially driving higher margins. The global expansion also provides natural hedging against regional market fluctuations.
- Gloperba® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
- Over
70% of gout patients have comorbid conditions that may require dose adjustments, and such patients could be a potential target population for Gloperba®1 - Over
17% of gout patients on colchicine experienced severe gastrointestinal side effects like diarrhea. These patients may benefit from flexible dosing offered by Gloperba®2 - Unlike other colchicine formulations, GLOPERBA® liquid oral solution allows for precision dosing and reduction of daily dose in patients with severe renal impairment (0.3 mg/day).
- The worldwide incidence of gout flares is estimated to be around 0.1 to
0.3% of the population, with a significantly higher prevalence in males compared to females, and a rising trend due to factors like increasing obesity rates and aging populations; however, exact figures can vary depending on the study and region analyzed.3 - The global population of individuals with gout increased in the past 30 years from 22 million (
95% UI 17.52-27.37) to 53 million (95% UI 43.38-66.34).4
PALO ALTO, Calif., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, in neurodegenerative and cardiometabolic disease, today announced that it has entered into an amendment (the “Amendment”) to its existing license agreement with Romeg Therapeutics, LLC (“Romeg”), entered into in June 2022, for ex-US rights to Gloperba®. Romeg had previously granted Scilex an exclusive license to commercialize Gloperba® only in the U.S.
Gloperba® is taken orally like cough syrup. The dosage of 0.6mg per 5ml (teaspoon) can fill that important void in treatment where patients may have difficulty swallowing pills. It can also provide more adjustable dosing, titration and dose-reduction options in specific populations, especially for gout patients with renal or hepatic impairment and reduce side effects with the goal to improve patient convenience and disease management.
According to Nature Reviews Rheumatology, gout is a common chronic crystal deposition disorder that affects between <
For more information on Scilex Holding Company, refer to www.scilexholding.com.
For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com.
For more information on Scilex Holding Company Sustainability Report, refer to www.scilexholding.com/investors/sustainability.
For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.
For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.
For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.
https://www.facebook.com/scilex.pharm
https://www.linkedin.com/company/scilex-holding-company/
About Scilex Holding Company
Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system)
In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system)
Scilex Holding Company is headquartered in Palo Alto, California.
About Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc. (“Semnur”) is a clinical-late stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.
Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, California
About ROMEG Therapeutics, LLC
ROMEG Therapeutics, LLC, is a privately held, revenue-generating, specialty pharmaceutical company based in Woburn, Mass. The company’s mission is to develop new FDA-approved therapies by formulating novel dosage forms, improving the design and function of existing approved drugs, and expanding clinical indications for use of those drugs, thereby bringing greater value to earlier scientific discovery. The company’s first FDA-approved drug, Gloperba® (colchicine oral solution) was launched by commercial partner Scilex in the US in 2024. The company has two active pipeline programs targeting Sjogren’s syndrome, and continues to focus on developing a broad intellectual property portfolio to offer novel therapies to provide patients and physicians better treatment options. For more information, visit www.romegrx.com.
Forward-Looking Statements
This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Gloperba being the first and only liquid oral version of the anti-gout medicine, Scilex’s plans to commercialize Gloperba and the potential for the amended license agreement to accelerate Scilex’s commercialization plans, Scilex’s proposed joint venture with IPMC Company and the potential development and commercialization of treatments for obesity, neurodegenerative, cardiometabolic disease.
Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: Scilex’s ability to commercialize GLOPERBA outside of the US, Scilex’s ability to consummate a joint venture or any other transaction with IPMC Company and develop and commercialize treatments for obesity, neurodegenerative, cardiometabolic disease; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to COVID-19 (and other similar disruptions); the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file with the SEC, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.
Contacts:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Website: www.scilexholding.com
References
- Comorbidities of Gout and Hyperuricemia in the US General Population: NHANES 2007-2008
- Stewart et al. Arthritis Research & Therapy (2020) 22:28; https://doi.org/10.1186/s13075-020-2120-7
- https://www.sciencedirect.com/science/article/pii/S0049017220301220
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10285625/
SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.
Gloperba® is the subject of an exclusive, transferable license to Scilex Holding Company to use the registered trademark.
ELYXYB® is a registered trademark owned by Scilex Holding Company.
All other trademarks are the property of their respective owners.
© 2025 Scilex Holding Company All Rights Reserved.
FAQ
What are the key benefits of Gloperba® compared to other colchicine formulations?
How large is the potential market for SCLX's Gloperba®?
What percentage of gout patients could benefit from Gloperba's flexible dosing?
What are the main side effects concerns for Gloperba® (SCLX)?
How has SCLX expanded its commercialization rights for Gloperba® in 2024?
